350 related articles for article (PubMed ID: 28389027)
1. Role of PET-CT with
Puche-Sanz I; Triviño-Ibáñez E; Vázquez-Alonso F; Llamas-Elvira JM; Cózar-Olmo JM; Rodríguez-Fernández A
Actas Urol Esp; 2017 Sep; 41(7):437-444. PubMed ID: 28389027
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of 18F-fluorocoline PET/CT in prostate cancer patients with biochemical recurrence: Influence of PSA kinetics and hormone therapy.
Triviño-Ibáñez EM; Puche-Sanz I; Gómez-Río M; Cózar Olmo JM; Llamas-Elvira JM; Rodríguez-Fernández A
Med Clin (Barc); 2019 Jul; 153(2):56-62. PubMed ID: 30660434
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
4. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
[TBL] [Abstract][Full Text] [Related]
5. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of
López Rodríguez E; Tirado Hospital JL; Álvarez Pérez RM; Gómez Izquierdo L; Jiménez-Hoyuela JM
Actas Urol Esp (Engl Ed); 2020; 44(6):437-443. PubMed ID: 32576406
[TBL] [Abstract][Full Text] [Related]
7. PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection?
Chiaravalloti A; Di Biagio D; Tavolozza M; Calabria F; Schillaci O
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1418-24. PubMed ID: 26791373
[TBL] [Abstract][Full Text] [Related]
8. Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography.
Simone G; Di Pierro GB; Papalia R; Sciuto R; Rea S; Ferriero M; Guaglianone S; Maini CL; Gallucci M
World J Urol; 2015 Oct; 33(10):1511-8. PubMed ID: 25577130
[TBL] [Abstract][Full Text] [Related]
9. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
[TBL] [Abstract][Full Text] [Related]
10. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
[TBL] [Abstract][Full Text] [Related]
11. Contribution of
Gómez-de la Fuente FJ; Martínez-Rodríguez I; de Arcocha-Torres M; Quirce R; Jiménez-Bonilla J; Martínez-Amador N; Banzo I
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(3):156-162. PubMed ID: 29137875
[TBL] [Abstract][Full Text] [Related]
12. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
13. A pilot study of the utility of choline PET-CT in prostate cancer biochemical relapse following radical prostatectomy.
Tan H; Joseph D; Loh NK; McCarthy M; Leong E; Siew T; Segard T; Morandeau L; Trevenen M; Francis RJ
J Med Imaging Radiat Oncol; 2016 Jun; 60(3):374-81. PubMed ID: 27094471
[TBL] [Abstract][Full Text] [Related]
14. Dual-phase (18)F-fluorocholine PET/CT to detect locoregional recurrence of prostate cancer: comparison between each time point of imaging and a summation scan.
Tong AK; Zhang ZX; Zaheer S; Yan XS
Clin Imaging; 2016; 40(3):486-91. PubMed ID: 27133692
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility and therapeutic impact of PET/CT [
Sánchez N; Valduvieco I; Ribal MJ; Campos F; Casas F; Nicolau C; Salvador R; Mellado B; Jorcano S; Fuster D; Paredes P
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):284-291. PubMed ID: 32467000
[TBL] [Abstract][Full Text] [Related]
16. [PET/CT with 18F-Fluorocholine in Patients with Prostatic Cancer in Biochemical Recurrence].
Lapa P; Silva R; Saraiva T; Figueiredo A; Ferreira R; Costa G; Lima JP
Acta Med Port; 2016 Mar; 29(3):182-92. PubMed ID: 27285094
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?
Heinisch M; Dirisamer A; Loidl W; Stoiber F; Gruy B; Haim S; Langsteger W
Mol Imaging Biol; 2006; 8(1):43-8. PubMed ID: 16315004
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
[TBL] [Abstract][Full Text] [Related]
19. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.
Marzola MC; Chondrogiannis S; Ferretti A; Grassetto G; Rampin L; Massaro A; Castellucci P; Picchio M; Al-Nahhas A; Colletti PM; Marcolongo A; Rubello D
Clin Nucl Med; 2013 Jan; 38(1):e26-32. PubMed ID: 23242060
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of
Samper Ots P; Luis Cardo A; Vallejo Ocaña C; Cabeza Rodríguez MA; Glaria Enríquez LA; Couselo Paniagua ML; Olivera Vegas J
Clin Transl Oncol; 2019 Jun; 21(6):766-773. PubMed ID: 30448957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
